NDAORALTABLET
Approved
Oct 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
18
Data completeness
3/8 — Basic
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VELSIPITY (etrasimod) is an oral small-molecule sphingosine-1-phosphate (S1P) receptor modulator approved by the FDA in October 2023. It represents a new therapeutic option in the immunology space, designed to modulate immune cell trafficking. The drug is positioned as a once-daily oral alternative in its therapeutic category.
Growth9.8 years to LOE
Early-stage growth product with significant commercial runway and opportunity for team expansion in the upcoming 2-3 years.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (18)
Etrasimod as Prevention of Pouchitis
Started Jun 2026
40 enrolled
Pouchitis
A Study of How the Medicine Called "Etrasimod" Works in Children With the Gut Disease Called Ulcerative Colitis
Started May 2026
24 enrolled
Colitis, Ulcerative
An Observational Study to Learn About Velsipity After Long Term Use in Patients With Ulcerative Colitis
Started Apr 2026
1 enrolled
Ulcerative Colitis (UC)
Etrasimod for Immune Checkpoint Inhibitor Diarrhea and Colitis
Started Jan 2026
0Immune Checkpoint Inhibitor-Related Diarrhea and Colitis
A Study to Learn How the Study Medicine Called Etrasimod is Taken up Into Blood and Breastmilk of Healthy Breastfeeding Women
Started Aug 2025
8 enrolled
Healthy Participant
Worked on VELSIPITY at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.